Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

June 2023

Effect of Body Mass Index on Treatment Response of Biologic/ Targeted-Synthetic DMARDs in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Axial Spondyloarthritis. A Systematic Review

Autoimmunity Reviews 22 (2023) 103357

Chrysoula G. Gialouri,

Maria Pappa,

Gerasimos Evangelatos,

Elena Nikiphorou,

George E. Fragoulis

The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.

Keywords:

April 2023

Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance

Ann Rheum Dis. 2023;82(7):901-910 doi: 10.1136/ard-2022-223715

Kristensen LE,

Danese S,

Yndestad A,

Wang C,

Nagy E,

Modesto I,

Rivas J,

Benda B

Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.